B2BROKER
18.11.2020 12:59:09 CET | Business Wire | Press release
B2Broker , a leading liquidity and technology provider of solutions to the Forex and crypto industry, has announced the launch of B2Margin , a white label margin exchange trading platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005593/en/
Margin trading, long present in the Forex markets, is now hugely popular in the fast-moving crypto sphere. Even large exchanges have now implemented leveraged trading thanks to its high profit-potential which is not achievable with spot trading these days.
B2Broker CEO and Founder, Arthur Azizov comments, “Margin trading has really increased in popularity despite the fact that derivative trading is what everyone tried to avoid when this was all starting out. Back in 2016, all traders preferred spot trading but business is now moving further towards derivative trading, justifying our decision to develop B2Margin and offer an attractive margin trading solution to our clients”.
Crypto margin trading offers brokers several compelling advantages in terms of more trading opportunities. The threat of exchange hacks is also minimised since trading with leverage reduces the amount of capital that is required to be held by an exchange.
About B2Margin
B2Margin is a White Label Margin Exchange trading platform developed by B2Broker that includes a range of functions including on-boarding, compliance, risk management, pricing and trading analytics.
Offering traders the opportunity to boost their trading with leverage, B2Margin is designed with both institutional and retail clients in mind, supporting multiple asset classes, such as FX, Metals, Indices, Energies, Stocks, ETFs, Cryptocurrencies CFDs and Spot/Cash Cryptocurrencies, with Futures Cryptocurrencies in the pipeline. This means that every broker will be able to provide two solutions to their clients - either leverage or cash trading on all the asset classes outlined.
Furthermore, B2Broker is in the final stages of completing its dividend distribution module which will allow broker-dealers to provide liquidity for STOs shares and cash equities.
Professional and Adaptive GUI
B2Margin offers a vast range of features with an advanced interface which meets all requirements from beginners to professional traders. By providing a customizable and adaptive layout, end users get to choose what they wish to see according to their needs and preferences. Trading instruments are grouped by classes with a customisable workspace which includes intuitive visualisation of market data, an extensive suite of trading tools and complete branding customisation. Some of the main features include:
Multiple Order Types
B2Margin offers multiple order types to support the most sophisticated trading strategies and provide users with a variety of options on how and when to enter and exit a trade. From Protection orders to Time in Force up to Pending orders, traders have everything they need to manage their trading activity.
Professional Сharts
This enables users to place trades, manage orders and work directly from our integrated charts and utilise a comprehensive suite of drawing tools, as well as over 50 technical indicators to analyze price trends.
Secure Wallets
The ability to withdraw, deposit and store your assets in your personal secure wallet. All assets are securely held in our offline storage system to protect users against any possible risks and threats.
Watchlist
Users have the opportunity to add their favourite instruments to the list and keep an eye on their current prices and 24 hour changes. Orders can then be placed straight from the Watchlist.
Order Book
The list of buy and sell orders organized by price is updated in real time and is an important indicator of market depth, reflecting the trading instrument's likely price trend.
Customised Leverage
For precise risk management, a broker’s clients can set their own custom leverage for each trade order. This is a highly anticipated unique feature that provides a competitive advantage in attracting clients to a business.
Risk Management
Along with the standard way of managing risk known as A-Book or B-Book, B2Margin allows brokers to use C-Book - a highly advanced feature for each broker’s dealing department.
A broker dealer will also be able to customise their spread, markup, swap and commissions for each user, particular accounts and by group.
Tech Support
B2Broker offers all its clients 24/7 technical support.
These features, with the added benefit of detailed account statements to volume trade reports, allow brokers to get complete control over their operations and maximise their business potential.
A Complete Customised Solution in 4 Weeks
A complete B2Margin brokerage solution can be implemented in under 4 weeks once the associated legalities and financial aspects are settled. B2Margin also includes B2Broker’s client traders room solution, B2Core , which allows for client onboarding, processing deposits and withdrawals, KYC and a host of other functions for a successful Brokerage business operation. Finally, B2Margin supports FIX API connection enabling brokers to offer their clients the ultimate in trading performance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005593/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom